Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

27.00 +1.34 (+5.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 Next >
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts
 
Via Benzinga
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co
 
Via Benzinga
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
Via The Motley Fool
What Analysts Are Saying About NewAmsterdam Pharma Co Stock
 
Via Benzinga
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation. 
Via Benzinga
Get insights into the top gainers and losers of Monday's pre-market session.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
7 Analysts Have This To Say About NewAmsterdam Pharma
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts
 
Via Benzinga
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)
 
Via Benzinga
Where NewAmsterdam Pharma Stands With Analysts
 
Via Benzinga
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma
 
Via Benzinga
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
 
Via Benzinga
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma
 
Via Benzinga
Expert Ratings For NewAmsterdam Pharma
 
Via Benzinga
Top 3 Health Care Stocks That May Collapse This Quarter
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
NewAmsterdam Pharma reports Phase 3 trial success for obicetrapib, achieving significant LDL-C reduction in ASCVD and HeFH patients on standard therapy. 
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug
The results bode well for an ongoing Phase 3 study examining cardiovascular outcomes. 
Via Investor's Business Daily
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
The company's combination treatment lowered LDL cholesterol by about 50% over 84 days. 
Via Investor's Business Daily
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
Needham initiates coverage on NewAmsterdam Pharma with a Buy rating, highlighting the potential of its cholesterol-lowering drug, obicetrapib. 
Via Benzinga
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results
NewAmsterdam Pharma announced positive topline results from the Phase 3 BROOKLYN trial for obicetrapib, showing a significant LDL-C reduction in HeFH patients. The stock fell 8.35% despite the success,... 
Via Benzinga
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.